The licensing agreement between Zymeworks and Daiichi Sankyo (https://www.daiichi-sankyo.ch/de/), started in 2016, has been expanded to allow Daiichi Sankyo to acquire licenses to Azymetric and Efect technology platforms in order to develop two additional bispecific antibody therapeutics. Zymeworks will receive an upfront technology access fee of US$18 million and may receive up to US$466.7 million in potential clinical, regulatory and commercial milestone payments.